AAAAAA

   
Results: 1-25 |
Results: 25
Development of a novel, nonimmunogenic, soluble human TNF receptor type I (sTNFR-I) construct in the baboon
Authors: Rosenberg, JJ Martin, SW Seely, JE Kinstler, O Gaines, GC Fukuzuka, K Rose, J Kohno, T Boyle, WJ Nelson, A Kieft, GL Marshall, WS Feige, U Gasser, J St Clair, J Frazier, J Abouhamze, A Moldawer, LL Edwards, CK
Citation: Jj. Rosenberg et al., Development of a novel, nonimmunogenic, soluble human TNF receptor type I (sTNFR-I) construct in the baboon, J APP PHYSL, 91(5), 2001, pp. 2213-2223
Combination cytokine therapy in rheumatoid arthritis: The next generation
Authors: Edwards, CK
Citation: Ck. Edwards, Combination cytokine therapy in rheumatoid arthritis: The next generation, JCR-J CLIN, 7(3), 2001, pp. S17-S24
Anti-interleukin-1 therapy in rheumatic diseases
Authors: Dayer, JM Feige, U Edwards, CK Burger, D
Citation: Jm. Dayer et al., Anti-interleukin-1 therapy in rheumatic diseases, CURR OP RH, 13(3), 2001, pp. 170-176
Defective localization of the NADPH phagocyte oxidase to Salmonella-containing phagosomes in tumor necrosis factor p55 receptor-deficient macrophages
Authors: Vazquez-Torres, A Fantuzzi, G Edwards, CK Dinarello, CA Fang, FC
Citation: A. Vazquez-torres et al., Defective localization of the NADPH phagocyte oxidase to Salmonella-containing phagosomes in tumor necrosis factor p55 receptor-deficient macrophages, P NAS US, 98(5), 2001, pp. 2561-2565
Apolipoprotein A-I inhibits the production of interleukin-1 beta and tumornecrosis factor-alpha by blocking contact-mediated activation of monocytesby T lymphocytes
Authors: Hyka, N Dayer, JM Modoux, C Kohno, T Edwards, CK Roux-Lombard, P Burger, D
Citation: N. Hyka et al., Apolipoprotein A-I inhibits the production of interleukin-1 beta and tumornecrosis factor-alpha by blocking contact-mediated activation of monocytesby T lymphocytes, BLOOD, 97(8), 2001, pp. 2381-2389
Defective fas ligand-mediated apoptosis predisposes to development of a chronic erosive arthritis subsequent to Mycoplasma pulmonis infection
Authors: Hsu, HC Zhang, HG Song, GG Xie, JP Liu, D Yang, P Fleck, M Wintersberger, W Zhou, T Edwards, CK Mountz, JD
Citation: Hc. Hsu et al., Defective fas ligand-mediated apoptosis predisposes to development of a chronic erosive arthritis subsequent to Mycoplasma pulmonis infection, ARTH RHEUM, 44(9), 2001, pp. 2146-2159
Glucocorticoid and Fas ligand induced mucosal lymphocyte apoptosis after burn injury
Authors: Fukuzuka, K Edwards, CK Clare-Salzler, M Copeland, EM Moldawer, LL Mozingo, DW
Citation: K. Fukuzuka et al., Glucocorticoid and Fas ligand induced mucosal lymphocyte apoptosis after burn injury, J TRAUMA, 49(4), 2000, pp. 710-716
Adeno-associated virus production of soluble tumor necrosis factor receptor neutralizes tumor necrosis factor a and reduces arthritis
Authors: Zhang, HG Xie, JF Yang, PG Wang, YM Xu, L Liu, D Hsu, HC Zhou, T Edwards, CK Mountz, JD
Citation: Hg. Zhang et al., Adeno-associated virus production of soluble tumor necrosis factor receptor neutralizes tumor necrosis factor a and reduces arthritis, HUM GENE TH, 11(17), 2000, pp. 2431-2442
TNF-alpha blockade by a dimeric TNF type I receptor molecule selectively inhibits adaptive immune responses
Authors: Colagiovanni, DB Suniga, MA Frazier, JL Edwards, CK Fleshner, M McCay, JA White, KL Shopp, GM
Citation: Db. Colagiovanni et al., TNF-alpha blockade by a dimeric TNF type I receptor molecule selectively inhibits adaptive immune responses, IMMUNOPH IM, 22(4), 2000, pp. 627-651
Lipopolysaccharide and D-galactosamine-induced hepatic injury is mediated by TNF-alpha and not by Fas ligand
Authors: Josephs, MD Bahjat, FR Fukuzuka, K Ksontini, R Solorzano, CC Edwards, CK Tannahill, CL MacKay, SLD Copeland, EM Moldawer, LL
Citation: Md. Josephs et al., Lipopolysaccharide and D-galactosamine-induced hepatic injury is mediated by TNF-alpha and not by Fas ligand, AM J P-REG, 278(5), 2000, pp. R1196-R1201
LPS-induced liver injury in D-galactosamine-sensitized mice requires secreted TNF-alpha and the TNF-p55 receptor
Authors: Nowak, M Gaines, GC Rosenberg, J Minter, R Bahjat, FR Rectenwald, J MacKay, SLD Edwards, CK Moldawer, LL
Citation: M. Nowak et al., LPS-induced liver injury in D-galactosamine-sensitized mice requires secreted TNF-alpha and the TNF-p55 receptor, AM J P-REG, 278(5), 2000, pp. R1202-R1209
Glucocorticoid-induced, caspase-dependent organ apoptosis early after burninjury
Authors: Fukuzuka, K Edwards, CK Clare-Salzler, M Copeland, EM Moldawer, LL Mozingo, DW
Citation: K. Fukuzuka et al., Glucocorticoid-induced, caspase-dependent organ apoptosis early after burninjury, AM J P-REG, 278(4), 2000, pp. R1005-R1018
Phase I/II trial of recombinant methionyl human tumor necrosis factor binding protein PEGylated dimer in patients with active refractory rheumatoid arthritis
Authors: Moreland, LW McCabe, DP Caldwell, JR Sack, M Weisman, M Henry, G Seely, JE Martin, SW Yee, CL Bendele, AM Frazier, JL Kohno, T Cosenza, ME Lyons, SA Dayer, JM Cohen, AM Edwards, CK
Citation: Lw. Moreland et al., Phase I/II trial of recombinant methionyl human tumor necrosis factor binding protein PEGylated dimer in patients with active refractory rheumatoid arthritis, J RHEUMATOL, 27(3), 2000, pp. 601-609
Tumor necrosis factor (TNF)-alpha-induced interleukin-8 in human blood cultures discriminates neutralization by the p55 and p75 TNF soluble receptors
Authors: Frishman, JI Edwards, CK Sonnenberg, MG Kohno, T Cohen, AM Dinarello, CA
Citation: Ji. Frishman et al., Tumor necrosis factor (TNF)-alpha-induced interleukin-8 in human blood cultures discriminates neutralization by the p55 and p75 TNF soluble receptors, J INFEC DIS, 182(6), 2000, pp. 1722-1730
X-ray crystal structure of a small antagonist peptide bound to interleukin-1 receptor type 1
Authors: Vigers, GPA Dripps, DJ Edwards, CK Brandhuber, BJ
Citation: Gpa. Vigers et al., X-ray crystal structure of a small antagonist peptide bound to interleukin-1 receptor type 1, J BIOL CHEM, 275(47), 2000, pp. 36927-36933
Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis
Authors: Bendele, AM Chlipala, ES Scherrer, J Frazier, J Sennello, G Rich, WJ Edwards, CK
Citation: Am. Bendele et al., Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis, ARTH RHEUM, 43(12), 2000, pp. 2648-2659
Treatment of rheumatoid arthritis with PEGylated recombinant human solubletumour necrosis factor receptor type I: a clinical update
Authors: Davis, MW Feige, U Bendele, AM Martin, SW Edwards, CK
Citation: Mw. Davis et al., Treatment of rheumatoid arthritis with PEGylated recombinant human solubletumour necrosis factor receptor type I: a clinical update, ANN RHEUM D, 59, 2000, pp. 41-43
Combination benefit of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) and dexamethasone or indomethacin in adjuvant arthritic rats
Authors: Bendele, AM McComb, J Gould, T Frazier, J Chlipala, ES Seely, J Kieft, G Wolf, J Edwards, CK
Citation: Am. Bendele et al., Combination benefit of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) and dexamethasone or indomethacin in adjuvant arthritic rats, INFLAMM RES, 48(8), 1999, pp. 453-460
Herpes simplex virus type 2 infection induced apoptosis in peritoneal macrophages independent of Fas and tumor necrosis factor-receptor signaling
Authors: Fleck, M Mountz, JD Hsu, HC Wu, JG Edwards, CK Kern, ER
Citation: M. Fleck et al., Herpes simplex virus type 2 infection induced apoptosis in peritoneal macrophages independent of Fas and tumor necrosis factor-receptor signaling, VIRAL IMMUN, 12(3), 1999, pp. 263-275
Effects of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) alone and in combination with methotrexate in adjuvant arthritic rats
Authors: Bendele, AM McComb, J Gould, T Frazier, J Chlipala, E Seely, J Kieft, G Edwards, CK
Citation: Am. Bendele et al., Effects of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) alone and in combination with methotrexate in adjuvant arthritic rats, CLIN EXP RH, 17(5), 1999, pp. 553-560
Use of recombinant human soluble TNF receptor in anorectic tumor-bearing rats
Authors: Torelli, GF Meguid, MM Moldawer, LL Edwards, CK Kim, HJ Carter, JL Laviano, A Fanelli, FR
Citation: Gf. Torelli et al., Use of recombinant human soluble TNF receptor in anorectic tumor-bearing rats, AM J P-REG, 46(3), 1999, pp. R850-R855
Antiarthritic activity of soluble tumor necrosis factor receptor type I forms in adjuvant arthritis: Correlation of plasma levels with efficacy
Authors: McComb, J Gould, T Chlipala, E Sennelo, G Frazier, J Kieft, G Seely, J Edwards, CK Bendele, A
Citation: J. Mccomb et al., Antiarthritic activity of soluble tumor necrosis factor receptor type I forms in adjuvant arthritis: Correlation of plasma levels with efficacy, J RHEUMATOL, 26(6), 1999, pp. 1347-1351
Induction of specific T cell tolerance by Fas ligand-expressing antigen-presenting cells
Authors: Zhang, H Xu, X Liu, D Liu, WM Yang, P Wang, Z Edwards, CK Bluethmann, H Mountz, JD Zhou, T
Citation: H. Zhang et al., Induction of specific T cell tolerance by Fas ligand-expressing antigen-presenting cells, J IMMUNOL, 162(3), 1999, pp. 1423-1430
PEGylated recombinant human soluble tumour necrosis factor receptor type I(r-Hu-sTNF-RI): novel high affinity TNF receptor designed for chronic inflammatory diseases
Authors: Edwards, CK
Citation: Ck. Edwards, PEGylated recombinant human soluble tumour necrosis factor receptor type I(r-Hu-sTNF-RI): novel high affinity TNF receptor designed for chronic inflammatory diseases, ANN RHEUM D, 58, 1999, pp. 73-81
Caspase-3-dependent organ apoptosis early after burn injury
Authors: Fukuzuka, K Rosenberg, JJ Gaines, GC Edwards, CK Clare-Salzler, M MacKay, SLD Moldawer, LL Copeland, EM Mozingo, DW
Citation: K. Fukuzuka et al., Caspase-3-dependent organ apoptosis early after burn injury, ANN SURG, 229(6), 1999, pp. 851-858
Risultati: 1-25 |